Dr. John Cush RheumNow
7 months 3 weeks ago
APP QD Clinic: Unweanable PMR APP QD Clinic: Unweanable PMR
Jack Cush, MD, and Leilani Law, APN, Dallas, TX, discuss a case regarding unweanable polymyalgia rheumatica. This APP QD clinic is presented as part of RheumNow's "Mission: APP Partners in Care" campaign during the https://t.co/Gl8iQJf1d2
Dr. John Cush RheumNow
7 months 3 weeks ago
INITIAL Goal is to not miss Red Flag Conditions (Fx, septic or crystal arthritis [all acute monarticular})! Then provide timely Dx & Rx by establishing acute vs chronic, inflam vs noninflam, & articular vs nonarticular.
Dr. John Cush RheumNow
7 months 3 weeks ago
Simple, low-cost strategy to Dx/Prognose GCA using CBC components NLR & PLR. 119 GCA vs 131 non-GCA pts - All CBC biomarkers signif assoc w/ ESR & CRP, but ESR/CRP did not predict mortality over time; YET mortality signif predicted by PLR, NLR, MLR (P value < 0.044) https://t.co/96Q7jDAiWt
DocXus docxusofficial
7 months 3 weeks ago
OPD Spotter
Identify it before the patient even sits
Diagnosis ❓ https://t.co/xM90YEp9jZ
Dr. John Cush RheumNow
7 months 3 weeks ago
British Society of Rheumatology Guideline for Monitoring DMARDs
The British Society of Rheumatology has published an update to their previous 2017 BSR/BHPR guideline regarding the use and monitoring of DMARDs (disease-modifying anti-rheumatic drugs) used to treat systemic https://t.co/7KNf6cIjfo
Dr. John Cush RheumNow
7 months 3 weeks ago
I agree that multiple assessments are needed to Dx NP-SLE; but my order of preference (for Dx yield) is: A) Hx c/w cerebritis; B) imaging to r/o other causes; C) CSF IgG index w/ Q albumin
Dr. John Cush RheumNow
7 months 3 weeks ago
The Essential Role of Physician Assistants in Rheumatology
Ready to bring a PA into your rheumatology practice? This blog post breaks down the key facts you need to know about PA training, scope of practice, and the recent changes to the profession's title. https://t.co/0aCTUpWMab
Dr. John Cush RheumNow
7 months 3 weeks ago
Focus on Guidelines https://t.co/Dgu0F5UiNY
Dr. John Cush RheumNow
7 months 3 weeks ago
2018 NHANES population survey of 28,040 individuals, 4168 (14.32%) identified with sleep disorders, and 1589 (4.28%) had #RA. Thus, sleep disorders were significantly associated with increased odds of RA (OR = 1.76, 95% CI: 1.46–2.13, P < 0.001). https://t.co/9O2MsLvwVe https://t.co/cBsm8Jt8Ks
The New England Journal of Medicine has published a phase III clinical trial showing that a B cell targeting monoclonal antibody, ianalumab, was effective in more than half of the patients with primary immune thrombocytopenia (ITP). Moreover, treatment maintained safe platelet counts without serious bleeding episodes for at least one year.
